Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)

Next Previous
Search
Trial Profile

A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Toripalimab (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms RENOTORCH
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 31 Dec 2024 Planned End Date changed from 30 Jun 2023 to 28 Feb 2025.
    • 31 Dec 2024 Planned primary completion date changed from 30 Jun 2023 to 28 Feb 2025.
    • 07 Apr 2024 According to a Shanghai Junshi Biosciences media release, based on the data of this study, the National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top